Seminars in Nephrology
Volume 24, Issue 3 , Pages 218-224 , May 2004

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy

  • John J Dillon

      Affiliations

    • Corresponding Author InformationAddress reprint requests to John J. Dillon, MD, Division of Nephrology, Mayo Clinic and Foundation, 200 1st Street, NW, Rochester, MN 55905, USA
    • Division of Nephrology, Mayo Clinic and Foundation, Rochester, Minnesota, USA

References 

  1. D’Amico G. Natural history of idiopathic IgA nephropathy (Role of clinical and histological prognostic factors). Am J Kidney Dis. 2000;36:227–237
  2. Haas M. Histologic subclassification of IgA nephropathy (A clinicopathologic study of 244 cases). Am J Kidney Dis. 1997;29:829–842
  3. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993–2000
  4. Remuzzi A, Perico N, Sangalli F, et al.  ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol. 1999;276:F457–F466
  5. Remuzzi G, Perna A, Benigni A. Proteins abnormally filtered throughout glomerular capillary have an intrinsic renal toxicity. Contrib Nephrol. 1996;118:164–172
  6. Perna A, Remuzzi G. Abnormal permeability to proteins and glomerular lesions (A meta-analysis of experimental and human studies). Am J Kidney Dis. 1996;27:34–41
  7. Jafar TH, Stark PC, Schmid CH, et al.  Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–1140
  8. Hernandez E, Toledo T, Alamo C, et al.  Elevation of von Willebrand factor levels in patients with IgA nephropathy (Effect of ACE inhibition). Am J Kidney Dis. 1997;30:397–403
  9. Maschio G, Cagnoli L, Claroni F, et al.  ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy (A multicentre, randomized, placebo-controlled study). Nephrol Dial Transplant. 1994;9:265–269
  10. Remuzzi A, Perticucci E, Ruggenenti P, et al.  Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int. 1991;39:1267–1273
  11. Perico N, Remuzzi A, Sangalli F, et al.  The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol. 1998;9:2308–2317
  12. Russo D, Pisani A, Balletta MM, et al.  Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999;33:851–856
  13. Laverman GD, Navis G, Henning RH, et al.  Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002;62:1020–1025
  14. Maschio G, Alberti D, Janin G, et al.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–945
  15. Feriozzi S, Pierucci A, Roscia E, et al.  Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy. J Hypertens Suppl. 1989;7:S63–S64
  16. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy (A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy). Am J Kidney Dis. 1994;23:247–254
  17. Bannister KM, Weaver A, Clarkson AR, et al.  Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol. 1995;111:184–193
  18. Maschio G, Alberti D, Locatelli F, et al.  Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol. 1999;33:S16–S20 discussion S41–43
  19. Ruggenenti P, Perna A, Mosconi L, et al.  Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). Kidney Int. 1998;53:1209–1216
  20. Ruggenenti P, Perna A, Gherardi G, et al.  Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359–364
  21. Ruggenenti P, Perna A, Gherardi G, et al.  Chronic proteinuric nephropathies (Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury). Am J Kidney Dis. 2000;35:1155–1165
  22. Jafar TH, Schmid CH, Landa M, et al.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87
  23. Lewis EJ, Hunsicker LG. Bain RPThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. [erratum appears in N Engl J Med 1993;330:152]: N Engl J Med. 1993;329:1456–1462
  24. Russo D, Minutolo R, Pisani A, et al.  Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18–25
  25. Nakao N, Yoshimura A, Morita H, et al.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) (A randomised controlled trial). [erratum appears in Lancet 2003;361:1230] Lancet. 2003;361:117–124
  26. Jacobsen P, Andersen S, Jensen BR, et al.  Additive Effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003;14:992–999
  27. Lacourciere Y, Belanger A, Godin C, et al.  Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58:762–769
  28. Mogensen CE, Neldam S, Tikkanen I, et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes (the candesartan and lisinopril microalbuminuria (CALM) study). BMJ. 2000;321:1440–1444
  29. Bhattacharjee R, Filler G. Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy. Pediatr Nephrol. 2002;17:302–304
  30. Ruilope LM, Aldigier JC, Ponticelli C, et al.  Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens. 2000;18:89–95
  31. Tiret L, Rigat B, Visvikis S, et al.  Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197–205
  32. Yoshida H, Mitarai T, Kawamura T, et al.  Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest. 1995;96:2162–2169
  33. Pei Y, Scholey J, Thai K, et al.  Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest. 1997;100:814–820
  34. Yorioka T, Suehiro T, Yasuoka N, et al.  Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy. Clin Nephrol. 1995;44:80–85
  35. Tanaka R, Iijima K, Murakami R, et al.  ACE gene polymorphism in childhood IgA nephropathy (Association with clinicopathologic findings). Am J Kidney Dis. 1998;31:774–779
  36. Hunley TE, Julian BA, Phillips JA, et al.  Angiotensin converting enzyme gene polymorphism (Potential silencer motif and impact on progression in IgA nephropathy). Kidney Int. 1996;49:571–577
  37. Santos NM, Ault BH, Gharavi AG, et al.  Angiotensin-converting enzyme genotype and outcome in pediatric IgA nephropathy. Pediatr Nephrol. 2002;17:496–502
  38. Lau YK, Woo KT, Choong HL, et al.  ACE gene polymorphism and disease progression of IgA nephropathy in Asians in Singapore. Nephron. 2002;91:499–503
  39. Schena FP, D’Altri C, Cerullo G, et al.  ACE gene polymorphism and IgA nephropathy (An ethnically homogeneous study and a meta-analysis). Kidney Int. 2001;60:732–740
  40. Suzuki S, Suzuki Y, Kobayashi Y, et al.  Insertion/deletion polymorphism in ACE gene is not associated with renal progression in Japanese patients with IgA nephropathy. Am J Kidney Dis. 2000;35:896–903
  41. Ong-Ajyooth S, Ong-Ajyooth L, Limmongkon A, et al.  The renin-angiotensin system gene polymorphisms and clinicopathological correlations in IgA nephropathy. J Med Assoc Thai. 1999;82:681–689
  42. Zhu X, Bouzekri N, Southam L, et al.  Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet. 2001;68:1139–1148
  43. Wang JG, Staessen JA. Genetic polymorphisms in the renin-angiotensin system (Relevance for susceptibility to cardiovascular disease). Eur J Pharmacol. 2000;410:289–302
  44. Fogarty DG, Harron JC, Hughes AE, et al.  A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes. 1996;45:1204–1208
  45. Prasad GV, Pinnaduwage D, Parkes RK, et al.  Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction. Transplantation. 2003;75:209–216
  46. Maruyama K, Yoshida M, Nishio H, et al.  Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy. Pediatr Nephrol. 2001;16:350–355
  47. Goto S, Narita I, Saito N, et al.  A(-20)C polymorphism of the angiotensinogen gene and progression of IgA nephropathy. Kidney Int. 2002;62:980–985
  48. Frimat L, Philippe C, Maghakian MN, et al.  Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy (IGARAS—A study of 274 men). J Am Soc Nephrol. 2000;11:2062–2067
  49. Perna A, Ruggenenti P, Testa A, et al.  ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney Int. 2000;57:274–281
  50. Praga M, Gutierrez E, Gonzalez E, et al.  Treatment of IgA nephropathy with ACE inhibitors (A randomized and controlled trial). J Am Soc Nephrol. 2003;14:1578–1583

PII: S0270-9295(04)00005-1

doi: 10.1016/j.semnephrol.2004.01.003

Seminars in Nephrology
Volume 24, Issue 3 , Pages 218-224 , May 2004

Article Tools